 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--- GRPH GraphiteBio--Graphite Bio, Inc. Nasdaq: GRPH, a clinical-stage, next-generation gene editing company harnessing high-efficiency precision gene correction to treat or cure serious diseases, today reported recent business progress and second quarter 2021 financial results. This has been a transformational period for Graphite Bio as we advance our next-generation gene editing platform to precisely find and replace any gene in the genome. We have built an outstan 